Compare Datadog Inc (DDOG) vs Moderna, Inc. (MRNA) Price & Performance

Datadog (DDOG) trades at $241.00, down 7.58% amid a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. The stock shows elevated valuation ratios (P/E 493.56, P/S 22.83) but maintains robust revenue growth (36% YoY in Q2) and a high gross profit margin of 79.51%. Recent insider selling and mixed technical indicators contrast with an 83% analyst buy rating.

Outlook: Long-term growth driven by AI demand and net revenue retention above 120% supports upside to the $288.55 consensus target. Risks include valuation sensitivity, customer concentration, and execution pressure. The stock presents a growth opportunity with volatility near-term.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.